Oppenheimer assumed coverage on shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) in a research note published on Thursday morning, MarketBeat reports. The firm issued an outperform rating and a $35.00 price objective on the stock.
OnKure Therapeutics Stock Performance
NASDAQ OKUR opened at $18.42 on Thursday. OnKure Therapeutics has a fifty-two week low of $9.80 and a fifty-two week high of $86.70. The company has a market cap of $61.52 million, a PE ratio of -1.10 and a beta of 0.21.
OnKure Therapeutics Company Profile
Want More Great Investing Ideas?
Read More
- Five stocks we like better than OnKure Therapeutics
- 5 discounted opportunities for dividend growth investors
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- The Significance of Brokerage Rankings in Stock Selection
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
